147 related articles for article (PubMed ID: 37779428)
1. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
Wu J; Subbiah V
Cancer Res; 2023 Oct; 83(19):3159-3161. PubMed ID: 37779428
[TBL] [Abstract][Full Text] [Related]
2. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.
Gou X; Kim BJ; Anurag M; Lei JT; Young MN; Holt MV; Fandino D; Vollert CT; Singh P; Alzubi MA; Malovannaya A; Dobrolecki LE; Lewis MT; Li S; Foulds CE; Ellis MJ
Cancer Res; 2023 Oct; 83(19):3237-3251. PubMed ID: 37071495
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
4. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
Syed YY
Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
6. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
[TBL] [Abstract][Full Text] [Related]
7. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
8. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
[TBL] [Abstract][Full Text] [Related]
9. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
[TBL] [Abstract][Full Text] [Related]
10. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
Gou X; Anurag M; Lei JT; Kim BJ; Singh P; Seker S; Fandino D; Han A; Rehman S; Hu J; Korchina V; Doddapaneni H; Dobrolecki LE; Mitsiades N; Lewis MT; Welm AL; Li S; Lee AV; Robinson DR; Foulds CE; Ellis MJ
Cancer Res; 2021 Dec; 81(24):6259-6272. PubMed ID: 34711608
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
14. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
Nguyen L; Monestime S
Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
[TBL] [Abstract][Full Text] [Related]
15. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
[TBL] [Abstract][Full Text] [Related]
17. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract][Full Text] [Related]
18. Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.
Zheng ZZ; Xia L; Hu GS; Liu JY; Hu YH; Chen YJ; Peng JY; Zhang WJ; Liu W
Nucleic Acids Res; 2022 Oct; 50(18):10230-10248. PubMed ID: 36124682
[TBL] [Abstract][Full Text] [Related]
19. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Spanheimer PM; Cyr AR; Gillum MP; Woodfield GW; Askeland RW; Weigel RJ
Ann Surg; 2014 Apr; 259(4):793-9. PubMed ID: 24045439
[TBL] [Abstract][Full Text] [Related]
20. Pralsetinib treatment for multiple
Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
